Savara (SVRA) Enterprise Value (2010 - 2026)
Savara (SVRA) posted quarterly Enterprise Value of -$202.8 million for Q1 2026, down 17.54% year-over-year from -$245.9 million in Q1 2025, and up 13.96% quarter-over-quarter from -$235.7 million in Q4 2025.
Savara (SVRA) Enterprise Value (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Enterprise Value for 17 consecutive years, with -$202.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 17.54% year-over-year to -$202.8 million; the TTM figure through Mar 2026 stood at -$202.8 million (down 17.54% YoY), while the FY2025 annual figure was -$235.7 million, down 20.06% from the prior year.
- Enterprise Value climbed to -$202.8 million in Q1 2026 per SVRA's latest filing, from -$235.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$105.1 million in Q2 2023 and bottomed at -$235.7 million in Q4 2025.
- Historically, Enterprise Value has averaged -$156.9 million across 5 years, with a median of -$146.4 million in 2025.
- Annual changes were most pronounced in 2024 — Enterprise Value plunged 30.39% — and 2025, when it jumped 43.32%.
- Savara's Enterprise Value stood at -$125.9 million in 2022, then declined by 28.95% to -$162.3 million in 2023, then decreased by 20.95% to -$196.3 million in 2024, then declined by 20.06% to -$235.7 million in 2025, then climbed by 13.96% to -$202.8 million in 2026.
- Business Quant data shows SVRA's Enterprise Value at -$202.8 million in Q1 2026, -$235.7 million in Q4 2025, and -$124.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | -173.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -173.03 Mn |
| Mar 31, 2026 | -202.80 Mn |
| Dec 31, 2025 | -235.70 Mn |
| Sep 30, 2025 | -124.39 Mn |
| Jun 30, 2025 | -146.40 Mn |
| Mar 31, 2025 | -172.54 Mn |
| Dec 31, 2024 | -196.33 Mn |
| Sep 30, 2024 | -219.44 Mn |
| Jun 30, 2024 | -121.60 Mn |
| Mar 31, 2024 | -143.10 Mn |
| Dec 31, 2023 | -162.32 Mn |
| Sep 30, 2023 | -168.30 Mn |
| Jun 30, 2023 | -105.13 Mn |
| Mar 31, 2023 | -114.79 Mn |
| Dec 31, 2022 | -125.88 Mn |
| Sep 30, 2022 | -134.00 Mn |
| Jun 30, 2022 | -142.44 Mn |
| Mar 31, 2022 | -151.83 Mn |
| Dec 31, 2021 | -161.17 Mn |
| Sep 30, 2021 | -170.81 Mn |